Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

316 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011.
Antinori A, Marcotullio S, Ammassari A, Andreoni M, Angarano G, Armignacco O, Carosi G, Cinque P, d'Arminio Monforte A, Di Perri G, Ensoli B, Floridia M, Galli M, Mastroianni C, Matteelli A, Mazzotta F, Moroni M, Pal G, Puoti M, Puro V, Rizzardini G, Sagnelli E, Vella S, Vullo V, Lazzarin A; Italian HIV Guidelines Working Group. Antinori A, et al. Among authors: mazzotta f. New Microbiol. 2012 Apr;35(2):113-59. Epub 2012 Mar 31. New Microbiol. 2012. PMID: 22707127 Free article. No abstract available.
A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS.
Vella S, Floridia M, Dally LG, Tomino C, Fragola V, Weimer LE, Milazzo F, Mazzotta F, Moroni M, Pastore G, Scalise G, Sinicco A, Ortona L, De Rienzo B, Dianzani F. Vella S, et al. Among authors: mazzotta f. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Aug 15;12(5):462-9. doi: 10.1097/00042560-199608150-00004. J Acquir Immune Defic Syndr Hum Retrovirol. 1996. PMID: 8757422 Clinical Trial.
Italian multicentre study of didanosine compassionate use in advanced HIV infection. Italian BMS-906 Study Group.
d'Arminio Monforte A, Musicco M, Galli M, Paga C, La Regina A, Lazzarin A, Angarano G, Milazzo F, Gritti F, Arlotti M, Mazzotta F, Visco G, Aiuti F, Moroni M. d'Arminio Monforte A, et al. Among authors: mazzotta f. Eur J Clin Microbiol Infect Dis. 1997 Feb;16(2):135-42. doi: 10.1007/BF01709472. Eur J Clin Microbiol Infect Dis. 1997. PMID: 9105840 Clinical Trial.
A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection.
Floridia M, Vella S, Seeber AC, Tomino C, Fragola V, Weimer LE, Ricciardulli D, Milazzo F, Gritti FM, Mazzotta F, Ranieri S, Chiodo F, Moroni M, Cargnel A, Bassetti D, Giannini V, Cremoni L, Concia E, Sinicco A, Carosi G, Alberici F, Dianzani F. Floridia M, et al. Among authors: mazzotta f. J Infect Dis. 1997 Feb;175(2):255-64. doi: 10.1093/infdis/175.2.255. J Infect Dis. 1997. PMID: 9203645 Clinical Trial.
Relationship between HAART adherence and adipose tissue alterations.
Ammassari A, Antinori A, Cozzi-Lepri A, Trotta MP, Nasti G, Ridolfo AL, Mazzotta F, Wu AW, d'Arminio Monforte A, Galli M; AdICoNA Study Group. LipoICoNA Study Group. Ammassari A, et al. Among authors: mazzotta f. J Acquir Immune Defic Syndr. 2002 Dec 15;31 Suppl 3:S140-4. doi: 10.1097/00126334-200212153-00011. J Acquir Immune Defic Syndr. 2002. PMID: 12562038
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial.
Mazzotta F, Lo Caputo S, Torti C, Tinelli C, Pierotti P, Castelli F, Lazzarin A, Angarano G, Maserati R, Gianotti N, Ladisa N, Quiros-Roldan E, Rinehart AR, Carosi G; Genotipo-Fenotipo di Resistenza (GenPheRex) Group of the Italian Management Standardizzato di Terapia Antiretrovirale (MASTER) Cohort. Mazzotta F, et al. J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):268-80. doi: 10.1097/00126334-200303010-00005. J Acquir Immune Defic Syndr. 2003. PMID: 12626886 Clinical Trial.
Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients.
Torti C, Quiros-Roldan E, Keulen W, Scudeller L, Lo Caputo S, Boucher C, Castelli F, Mazzotta F, Pierotti P, Been-Tiktak AM, Buccoliero G, De Gennaro M, Carosi G, Tinelli C; GenPherex Study Group of the MaSTeR Cohort. Torti C, et al. Among authors: mazzotta f. J Infect Dis. 2003 Jul 15;188(2):194-201. doi: 10.1086/376512. Epub 2003 Jul 1. J Infect Dis. 2003. PMID: 12854073
HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations.
Scudeller L, Torti C, Quiros-Roldan E, Patroni A, Lo Caputo S, Moretti F, Mazzotta F, Donati E, Vivarelli A, Carosi G; GenPheRex Group of the MASTER Cohort. Scudeller L, et al. Among authors: mazzotta f. J Antimicrob Chemother. 2003 Nov;52(5):776-81. doi: 10.1093/jac/dkg456. Epub 2003 Oct 16. J Antimicrob Chemother. 2003. PMID: 14563897 Clinical Trial.
HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations.
Torti C, Quiros-Roldan E, Monno L, Patroni A, Saracino A, Angarano G, Tinelli C, Mazzotta F, Lo Caputo S, Pierotti P, Carosi G; GenPheRex PhenGen Study Groups of the MASTER Cohort. Torti C, et al. Among authors: mazzotta f. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1104-7. doi: 10.1097/00126334-200408150-00016. J Acquir Immune Defic Syndr. 2004. PMID: 15247566 Clinical Trial. No abstract available.
316 results